Your browser is no longer supported. Please, upgrade your browser.
Settings
BIOD Biodel Inc. daily Stock Chart
BIOD [NASD]
Biodel Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own5.66% Shs Outstand64.22M Perf Week-1.19%
Market Cap26.65M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float63.92M Perf Month-5.68%
Income-15.40M PEG- EPS next Q- Inst Own11.40% Short Float0.37% Perf Quarter33.87%
Sales- P/S- EPS this Y30.80% Inst Trans-15.99% Short Ratio0.52 Perf Half Y25.76%
Book/sh0.44 P/B0.94 EPS next Y- ROA-42.50% Target Price3.50 Perf Year-5.68%
Cash/sh0.48 P/C0.86 EPS next 5Y- ROE-45.70% 52W Range0.22 - 0.59 Perf YTD22.06%
Dividend- P/FCF- EPS past 5Y40.90% ROI- 52W High-29.66% Beta1.37
Dividend %- Quick Ratio11.30 Sales past 5Y- Gross Margin- 52W Low88.64% ATR0.03
Employees24 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)46.64 Volatility7.21% 7.21%
OptionableYes Debt/Eq0.00 EPS Q/Q59.80% Profit Margin- Rel Volume1.02 Prev Close0.44
ShortableYes LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume458.60K Price0.41
Recom3.00 SMA20-2.41% SMA501.39% SMA20019.16% Volume467,172 Change-4.60%
Dec-18-15Downgrade Ladenburg Thalmann Buy → Neutral
May-18-15Initiated ROTH Capital Buy $5
May-10-13Upgrade Ladenburg Thalmann Neutral → Buy $6
Apr-16-12Upgrade JMP Securities Mkt Perform → Mkt Outperform $3
May-26-11Initiated Global Hunter Securities Accumulate $5
Feb-04-11Reiterated Wedbush Outperform $7 → $5
Dec-10-10Reiterated Wedbush Outperform $10 → $7
Nov-02-10Reiterated Wedbush Outperform $17 → $10
Nov-02-10Downgrade Ladenburg Thalmann Buy → Neutral $14 → $2
Oct-19-10Initiated JMP Securities Mkt Perform
Mar-25-09Reiterated Wedbush Morgan Buy $10 → $16
Mar-25-09Reiterated Ladenburg Thalmann Buy $9.50 → $14
Dec-11-08Reiterated Ladenburg Thalmann Buy $11 → $9.50
Nov-20-08Reiterated Cantor Fitzgerald Buy $33 → $15
Sep-19-08Downgrade Argus Buy → Sell
Sep-11-08Initiated Oppenheimer Perform
Sep-08-08Reiterated Ladenburg Thalmann Buy $23 → $11
May-16-08Initiated Cantor Fitzgerald Buy $33
May-02-08Initiated Pacific Growth Equities Buy
Feb-27-08Initiated JP Morgan Overweight
Sep-26-16 04:30PM  Biodel Announces 2016 Annual Meeting of Stockholders Set for October 24, 2016; Outlines Plan to Regain Compliance With Nasdaq Listing Requirements Marketwired
Sep-22-16 06:03AM  BIODEL INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
Sep-09-16 04:09PM  BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agree
Aug-19-16 01:04PM  BIODEL INC Financials
Aug-12-16 06:04AM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events,
Aug-11-16 05:29PM  BIODEL INC Files SEC form 10-Q, Quarterly Report
04:34PM  Biodel Reports Third Quarter Fiscal Year 2016 Financial Results Marketwired
Jul-13-16 09:22AM  BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Jun-27-16 08:58AM  Research Report Initiated on Select Drug Manufacturers Equities +11.54%
May-26-16 09:30AM  The Zacks Analyst Blog Highlights: XenoPort, Biodel and AbbVie -19.57%
08:08AM  BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
May-25-16 03:02PM  Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well +21.05%
12:54PM  BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:38AM  Biodel/Albireo Limited to Combine; Focus on Liver Diseases
May-24-16 08:04PM  Biodel Inc. and Albireo Limited Agree to Combine Marketwired
May-10-16 04:03PM  BIODEL INC Files SEC form 10-Q, Quarterly Report
May-09-16 05:37PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits +7.89%
05:00PM  Biodel Reports Second Quarter Fiscal Year 2016 Financial Results Marketwired
Apr-01-16 05:02PM  BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Mar-24-16 09:15AM  BIODEL INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf +6.45%
Mar-02-16 05:49PM  BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-16-16 08:01AM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:05AM  Biodel Reports First Quarter Fiscal Year 2016 Financial Results Marketwired
Jan-29-16 08:57AM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:00AM  Biodel Announces Restructuring Update Marketwired
Jan-27-16 04:33PM  BIODEL INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities -7.69%
Jan-15-16 06:37AM  3 Biotech Stocks Under $10 to Trade for Big Gains at TheStreet +7.69%
Dec-28-15 08:25AM  Auris Medical Holding (EARS) Looks Good: Stock Up 23.8%
Dec-22-15 04:38PM  BIODEL INC Files SEC form 10-K, Annual Report
Dec-18-15 12:56PM  Biodel downgraded by Ladenburg Thalmann +34.78%
10:47AM  4 Stocks Under $10 Showing Great Upside Today Accesswire
Dec-17-15 04:58PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition -8.00%
04:14PM  Biodel Reports Fourth Quarter and Fiscal Year 2015 Financial Results Marketwired
07:07AM  Q4 2015 Biodel Inc Earnings Release - 4:00 pm ET
Dec-14-15 07:00AM  Biodel to Report Fourth Quarter and Fiscal Year 2015 Financial Results on December 17, 2015 Marketwired
Dec-07-15 04:58PM  Novartis (NVS) Unveils Positive Data on Leukemia Candidates -9.38%
Dec-03-15 04:55PM  Immunomedics, FDA Finalize Oncology Drug Study Design
Nov-27-15 09:57AM  What Do Hedge Funds Think of EnteroMedics Inc (ETRM)? at Insider Monkey +5.56%
Nov-24-15 05:11PM  Do Hedge Funds Love AEterna Zentaris Inc. (USA) (AEZS)? at Insider Monkey
10:36AM  AEterna Zentaris Inc. (USA) (AEZS) Making Another Monster Move Today at Insider Monkey
Nov-03-15 04:34PM  BIODEL INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
04:30PM  Biodel Announces Clinical and Corporate Updates Marketwired
Oct-19-15 04:30PM  Biodel Announces Data Presentations at the Diabetes Technology Society Conference Marketwired
09:30AM  New Strong Buy Stocks for October 19th
Oct-13-15 06:10AM  BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-12-15 07:00AM  Biodel Announces Removal of Partial Clinical Hold for BIOD-531 and Plans for Potential Expansion of Target Patient Population Marketwired
Sep-25-15 04:31PM  BIODEL INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transf
Sep-24-15 02:45PM  These 5 Healthcare Penny Stocks Are Poised To Jump at Insider Monkey
Sep-22-15 07:00AM  Biodel to Present at the Ladenburg Thalmann 2015 Healthcare Conference Marketwired -5.71%
Sep-15-15 05:08PM  BIODEL INC Files SEC form 8-K, Other Events
01:58PM  4 Stocks Under $10 Making Big Moves Higher at TheStreet
Sep-14-15 06:55PM  Biodel Announces Data Presentation at the 51st Annual Meeting of the EASD Marketwired
Sep-01-15 02:57PM  3 Breakout Biotech Stocks Trading for Under $10 at TheStreet +7.46%
Aug-16-15 08:12PM  10-Q for Biodel, Inc. at Company Spotlight
Aug-14-15 03:27PM  BIODEL INC Files SEC form 10-Q, Quarterly Report -23.16%
12:49PM  Edited Transcript of BIOD earnings conference call or presentation 13-Aug-15 9:00pm GMT
Aug-13-15 05:17PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:00PM  Biodel Reports Third Quarter Fiscal Year 2015 Financial Results Marketwired
07:07AM  Q3 2015 Biodel Inc Earnings Release - 4:00 pm ET
Aug-06-15 08:00AM  Biodel to Report Third Quarter Fiscal Year 2015 Financial Results on August 13, 2015 Marketwired
Jul-09-15 12:40PM  Galmed Inks Deal to Develop Non-Invasive Diagnostic Tool - Analyst Blog
Jun-29-15 10:04PM  Edited Transcript of BIOD presentation 24-Jun-15 6:00pm GMT
Jun-18-15 04:30PM  Biodel to Present at Two Upcoming Investor Conferences Marketwired
11:50AM  Radius Health Up on Positive Data on Fracture Candidate - Analyst Blog
Jun-17-15 12:40PM  Impax's Zomig Nasal Spray Gets FDA Nod for Pediatrics - Analyst Blog
Jun-08-15 04:31PM  BIODEL INC Files SEC form 8-K/A, Change in Directors or Principal Officers
Jun-03-15 08:09PM  10-Q/A for Biodel, Inc. at Company Spotlight
Jun-01-15 04:35PM  BIODEL INC Files SEC form 10-Q/A, Quarterly Report
May-28-15 04:00PM  Biodel to Present Data on Concentrated Ultra-Rapid-Acting/Basal Insulin and Glucagon at the 75th American Diabetes Association Scientific Sessions Marketwired
May-21-15 04:02PM  BIODEL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
07:00AM  Biodel Announces Phase 2b Clinical Trial Initiation of BIOD-531, the Company's Concentrated, Ultra-Rapid-Acting, Prandial/Basal Combination Insulin Candidate Marketwired
May-18-15 07:00AM  Biodel Appoints Ms. Arlene M. Morris to Its Board of Directors Marketwired
May-09-15 08:09PM  10-Q for Biodel, Inc. at Company Spotlight
May-07-15 05:30PM  BIODEL INC Files SEC form 10-Q, Quarterly Report
May-06-15 04:46PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:00PM  Biodel Reports Second Quarter Fiscal Year 2015 Financial Results Marketwired
07:07AM  Q2 2015 Biodel Inc Earnings Release - 4:00 pm ET
May-01-15 09:48AM  Biodel to Report Second Quarter Fiscal Year 2015 Financial Results on May 6, 2015 Marketwired
01:02AM  Biodel's Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior Usability Compared to Marketed Glucagon Kits in Human Factors Study at noodls
01:02AM  Biodel Announces Pricing of Public Offering of Common Stock at noodls
Apr-20-15 10:03AM  BIODEL INC Files SEC form 8-K, Other Events
Apr-16-15 06:03PM  Nasdaq stocks posting largest volume increases
Apr-15-15 10:42AM  BIODEL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agree +10.68%
08:00AM  Biodel Announces Pricing of Public Offering of Common Stock Marketwired
Apr-06-15 08:17AM  BIODEL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Biodel's Glucagon Emergency Management (GEM) Auto-Reconstitution Device Demonstrates Superior Usability Compared to Marketed Glucagon Kits in Human Factors Study Marketwired
Apr-01-15 12:15AM  Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial at noodls
12:15AM  Biodel to Present at the 27th Annual ROTH Conference at noodls
Mar-18-15 01:30PM  BIODEL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Mar-16-15 08:41AM  BIODEL INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
07:00AM  Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial Marketwired
Mar-04-15 08:00AM  Biodel to Present at the 27th Annual ROTH Conference Marketwired
Mar-01-15 01:56AM  Biodel Reports First Quarter Fiscal Year 2015 Financial Results at noodls
Feb-14-15 07:07PM  10-Q for Biodel, Inc. at Company Spotlight
Feb-12-15 05:01PM  BIODEL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
05:00PM  BIODEL INC Files SEC form 10-Q, Quarterly Report
04:06PM  Pacira Resolves Promotion Issues Related to Exparel - Analyst Blog
04:00PM  Biodel Reports First Quarter Fiscal Year 2015 Financial Results Marketwired
07:07AM  Q1 2015 Biodel Inc Earnings Release - 4:00 pm ET CCBN
Feb-09-15 05:58PM  UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog Zacks
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency management (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose. The company completed a Phase 1 clinical trial to assess the pharmacokinetic and pharmacodynamic profiles of BIOD-961, the reconstituted glucagon formulation intended for use in the GEM device. It also develops ultra-rapid-acting proprietary insulin formulations, such as BIOD-531, a concentrated ultra-rapid-acting insulin formulation. In addition, the company develops pre-clinical analog-based ultra-rapid-acting insulin formulations using insulin lispro, the active pharmaceutical ingredient in Humalog, as well as insulin aspart, the active pharmaceutical ingredient in NovoLog. Biodel Inc. was founded in 2003 and is headquartered in Danbury, Connecticut.